Literature DB >> 32798374

Behavioral Tasks Evaluating Schizophrenia-like Symptoms in Animal Models: A Recent Update.

Mary Jasmin Ang1, Sueun Lee1, Jong-Choon Kim1, Sung-Ho Kim1, Changjong Moon1.   

Abstract

BACKGROUND: Schizophrenia is a serious mental illness that affects more than 21 million people worldwide. Both genetics and the environment play a role in its etiology and pathogenesis. Symptoms of schizophrenia are mainly categorized into positive, negative, and cognitive. One major approach to identify and understand these diverse symptoms in humans has been to study behavioral phenotypes in a range of animal models of schizophrenia.
OBJECTIVE: We aimed to provide a comprehensive review of the behavioral tasks commonly used for measuring schizophrenia-like behaviors in rodents together with an update of the recent study findings.
METHODS: Articles describing phenotypes of schizophrenia-like behaviors in various animal models were collected through a literature search in Google Scholar, PubMed, Web of Science, and Scopus, with a focus on advances over the last 10 years.
RESULTS: Numerous studies have used a range of animal models and behavioral paradigms of schizophrenia to develop antipsychotic drugs for improved therapeutics. In establishing animal models of schizophrenia, the candidate models were evaluated for schizophrenia-like behaviors using several behavioral tasks for positive, negative, and cognitive symptoms designed to verify human symptoms of schizophrenia. Such validated animal models were provided as rapid preclinical avenues for drug testing and mechanistic studies.
CONCLUSION: Based on the most recent advances in the field, it is apparent that a myriad of behavior tests are needed to confirm and evaluate the congruency of animal models with the numerous behaviors and clinical signs exhibited by patients with schizophrenia. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Schizophrenia; animal model; behavioral task; environment; genetic; symptom

Year:  2021        PMID: 32798374     DOI: 10.2174/1570159X18666200814175114

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


  3 in total

Review 1.  Polyamines and polyamine-metabolizing enzymes in schizophrenia: Current knowledge and concepts of therapy.

Authors:  Hans-Gert Bernstein; Gerburg Keilhoff; Gregor Laube; Henrik Dobrowolny; Johann Steiner
Journal:  World J Psychiatry       Date:  2021-12-19

2.  Reelin Alterations, Behavioral Phenotypes, and Brain Anomalies in Schizophrenia: A Systematic Review of Insights From Rodent Models.

Authors:  Ana C Sánchez-Hidalgo; Celia Martín-Cuevas; Benedicto Crespo-Facorro; Nathalia Garrido-Torres
Journal:  Front Neuroanat       Date:  2022-03-24       Impact factor: 3.856

3.  Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.

Authors:  Ming-Huan Zhu; Zhen-Jing Liu; Qiong-Yue Hu; Jia-Yu Yang; Ying Jin; Na Zhu; Ying Huang; Dian-Hong Shi; Min-Jia Liu; Hong-Yang Tan; Lei Zhao; Qin-Yu Lv; Zheng-Hui Yi; Feng-Chun Wu; Ze-Zhi Li
Journal:  Mil Med Res       Date:  2022-10-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.